This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
Hycroft ($HYMC) Reports 55% Resource Growth at Nevada Mine
Hycroft Mining Holding Corporation ($HYMC) said its updated independent mineral resource estimate shows 55% growth in measured and indicated gold and silver resources, further expanding what is already one of the largest precious metals deposits in the U.S.
The updated estimate now outlines:
- 16.4 million ounces of gold (Measured & Indicated)
- 562.6 million ounces of silver (Measured & Indicated)
- An initial high-grade silver resource of 90.2 million ounces
The company said the increase reflects new drilling, updated geological modeling, and improved metallurgy. Over the past 14 months, Hycroft drilled 70 holes and defined new high-grade silver zones at its Brimstone and Vortex systems, which remain open for further expansion.
Strong Metallurgy Supports Economics
Test work showed solid recovery rates:
- Gold recovery: ~83%
- Silver recovery: ~78%
The company is evaluating two processing routes:
- Pressure oxidation (POX), which showed strong recoveries
- A potential roasting alternative, which could create an additional revenue stream by producing sulfuric acid as a by-product
Management said early analysis suggests roasting could have comparable capital and operating costs to POX, while potentially improving project economics.
Why This Matters
Higher resources combined with strong recovery rates are key steps toward defining a future commercial mine plan. The updated technical report replaces Hycroft’s 2023 initial assessment and reflects significant geological re-interpretation of the deposit.
Hycroft operates the large Hycroft Mine in Nevada and is focused on advancing the project toward development.
Stock Price Reaction
$HYMC shares jumped 21% following the announcement, reflecting strong investor response to the substantial resource expansion and improved processing outlook.
Meta Platforms ($META) and NVIDIA ($NVDA) Expand AI Infrastructure Partnership
Meta and NVIDIA announced a multiyear, multigenerational strategic partnership focused on AI infrastructure spanning on-premises data centers, cloud deployments, CPUs, GPUs and networking.
According to the companies, Meta will build hyperscale AI data centers optimized for both model training and inference as part of its long-term AI roadmap. The partnership includes large-scale deployment of NVIDIA CPUs and millions of NVIDIA Blackwell and Rubin GPUs, along with integration of NVIDIA Spectrum-X Ethernet networking.
Meta will deploy GB300-based systems and adopt a unified architecture across its data centers and NVIDIA Cloud Partner environments. The collaboration also includes expanded deployment of Arm-based NVIDIA Grace CPUs, which, according to the companies, improve performance per watt in production workloads.
Meta and NVIDIA are also collaborating on potential large-scale deployment of NVIDIA Vera CPUs beginning in 2027, further expanding Meta’s AI compute footprint.
Networking and Confidential Computing
Meta will use NVIDIA Spectrum-X Ethernet switches to support AI-scale networking across its infrastructure. The companies stated that this should enhance throughput, utilization and power efficiency.
Meta has also adopted NVIDIA Confidential Computing for WhatsApp private processing. According to the company, this enables AI-powered features while maintaining user data privacy. The collaboration may expand confidential computing use cases across additional Meta platforms.
Engineering teams from both companies are engaged in infrastructure and software co-design. According to NVIDIA, this deep integration is intended to optimize Meta’s large-scale AI workloads, including recommendation systems and next-generation AI services used by billions of users.
Stock Price Reaction
$META and $NVDA shares did not show a significant move specifically tied to this announcement.
ImmunityBio ($IBRX) Receives European Approval for Bladder Cancer Immunotherapy
ImmunityBio announced that the European Commission has granted conditional marketing authorization for its immunotherapy in combination with BCG to treat a specific form of early-stage bladder cancer that no longer responds to standard therapy.
According to the company, this is the first approved immunotherapy in Europe for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Until now, patients in the European Union had no authorized drug option and often faced bladder removal surgery as the main alternative.
The approval was supported by clinical data showing a 71% complete response rate, meaning most patients had no visible signs of cancer after treatment. Responses lasted a median of 26.6 months, with some patients remaining cancer-free for more than four years, according to the company. Most side effects were reported as mild to moderate.
With this decision, the treatment is now authorized in 33 countries across the United States, United Kingdom, Saudi Arabia and the European Union. The company stated it will continue providing long-term data as required under the EU’s conditional approval framework.
Stock Price Reaction
$IBRX stock surged about 41% after the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
